Short answer: The ibandronate label lists back pain, dyspepsia, pain in the arms or legs, diarrhea, headache and myalgia as the most common side effects (over 5%). In a 2-year trial of 150 mg monthly, abdominal pain was 7.8%, hypertension 6.3%, dyspepsia and arthralgia 5.6% each. Warnings cover esophagus irritation, low calcium, jaw bone death and unusual thigh fractures. There is no boxed warning.
What Ibandronate Tablets is approved for: Ibandronate sodium tablets, the generic form of Boniva, are a bisphosphonate approved to treat and prevent osteoporosis in postmenopausal women. The label says ibandronate increases bone mineral density and reduces vertebral fractures (section 1.1). The best length of use has not been set, and people at low fracture risk may be considered for stopping after 3 to 5 years (section 1.2).
Source
Ibandronate Sodium Tablets, for oral use, prescribing information and Medication Guide. Bionpharma. DailyMed, version published August 27, 2026. DailyMed setid 6ca94cce-a2bb-421f-bd8f-6b14bc2bd985
No. The current Ibandronate Tablets label has no boxed warning.
These are the label's own numbers from the Adverse Reactions section. Where the label compares with placebo (a dummy treatment), both columns are shown, so you can see how much more often a reaction happened on Ibandronate Tablets.
| Adverse event | Ibandronate 2.5 mg daily (n=395) | Ibandronate 150 mg monthly (n=396) |
|---|---|---|
| Hypertension | 7.3 | 6.3 |
| Dyspepsia | 7.1 | 5.6 |
| Nausea | 4.8 | 5.1 |
| Diarrhea | 4.1 | 5.1 |
| Constipation | 2.5 | 4 |
| Abdominal pain | 5.3 | 7.8 |
| Arthralgia | 3.5 | 5.6 |
| Back pain | 4.3 | 4.5 |
| Pain in extremity | 1.3 | 4 |
| Localized osteoarthritis | 1.3 | 3 |
| Myalgia | 0.8 | 2 |
| Muscle cramp | 2 | 1.8 |
| Influenza | 3.8 | 4 |
| Nasopharyngitis | 4.3 | 3.5 |
| Bronchitis | 3.5 | 2.5 |
| Urinary tract infection | 1.8 | 2.3 |
| Upper respiratory tract infection | 2 | 2 |
| Headache | 4.1 | 3.3 |
| Dizziness | 1 | 2.3 |
| Influenza-like illness | 0.8 | 3.3 |
| Rash | 1.3 | 2.3 |
| Insomnia | 0.8 | 2 |
Two-year trial comparing 150 mg monthly with 2.5 mg daily; there was no placebo group. Values are percent of patients. After one year, stopping because of adverse events was 9% on 2.5 mg daily and 8% on 150 mg monthly. Abdominal pain includes upper abdominal pain; influenza-like illness includes acute phase reaction; rash combines several rash and dermatitis terms.
Acute phase reaction symptoms (within 3 days of the monthly dose, lasting 7 days or less) over two years: 9% on 150 mg monthly vs 3% on 2.5 mg daily. Influenza-like illness was reported by 2% on monthly dosing and no one on daily dosing.
After one year, all-cause deaths were 0.3% in both groups and serious adverse events were 7% on 150 mg monthly vs 5% on 2.5 mg daily.
Two patients on 150 mg monthly had eye inflammation: one uveitis and one scleritis.
In a 1-year placebo-controlled prevention study of 160 postmenopausal women without osteoporosis, the overall pattern of adverse events was similar.
Reported after approval: allergic reactions including anaphylaxis with deaths, angioedema, bronchospasm, asthma flare-ups, rash and Stevens-Johnson syndrome; low calcium; rare severe bone, joint or muscle pain; unusual thigh and other fractures; and osteonecrosis of the jaw and other face and ear sites, including the outer ear canal.
The Warnings and Precautions part of the label lists these. Each line gives the label's heading and what it means in plain words.
Who should not use it. People with esophagus problems that slow emptying, such as a narrowing or achalasia; people who cannot stand or sit upright for at least 60 minutes; people with low blood calcium; and anyone allergic to ibandronate or its ingredients. Anaphylaxis has been reported.
Esophagus and stomach irritation. Ibandronate can irritate the upper digestive tract. Esophagus inflammation, ulcers and erosions, sometimes with bleeding and rarely narrowing or a tear, have been reported with oral bisphosphonates. The risk appears greater in people who lie down after a dose, skip the full glass of water, or keep taking it after symptoms start. It is stopped for trouble or pain swallowing, chest pain or new or worse heartburn.
Low blood calcium. Low calcium and other bone mineral problems are treated before starting, and calcium and vitamin D are taken if diet is not enough.
Bone, joint and muscle pain. Severe, sometimes disabling pain has been reported, starting from one day to several months after starting. Most people improved after stopping, and stopping is considered if severe symptoms develop.
Osteonecrosis of the jaw. Jaw bone death has been reported, usually with tooth extraction or local infection with slow healing. Risk factors include invasive dental work, cancer, chemotherapy, steroids and poor mouth care, and the risk may grow with longer use.
Unusual thigh and other fractures. Low-trauma fractures of the thigh bone shaft and other bones have been reported, sometimes on both sides, often after weeks to months of dull, aching thigh pain. New thigh or groin pain is checked for a fracture, and pausing the bisphosphonate is considered.
Severe kidney impairment. Ibandronate is not recommended when creatinine clearance is under 30 mL/min.
From the Medication Guide that comes with Ibandronate Tablets:
Dose Track has a side-effect log. Each entry records the symptom, a severity (none, mild, moderate, severe or life-threatening), the date and an optional note, and can be tied to a specific dose or logged on its own. The history screen shows what you logged over time, which makes it easier to tell your prescriber when a reaction started and whether it is easing. The app records what you enter; it does not judge whether a symptom is serious. For anything on the label's call-your-doctor list, call your doctor.
This page is what the FDA label says, in plain words. It is not medical advice. Follow your prescriber, and ask them or your pharmacist about anything here.